October 15, 2008 - Julio Palmaz, M.D. made his mark on the medical world 20 years ago with the invention of the stent which revolutionized cardiac care, and now more than a million people each year undergo coronary artery stenting to repair clogged arteries.

October 14, 2008 - St. Jude Medical Inc. said today at TCT 2008 that the FDA and European CE Mark approval of the Angio-Seal Evolution Vascular Closure Device.

October 14, 2008 - At TCT 2008, Philips will showcase CT Comprehensive Cardiac Analysis (CCA) with 3D-QCA, which is used to perform detailed evaluation of the coronary arteries and advanced ventricular functional analysis.

Designed to help hospitals integrate CT directly with interventional cardiovascular procedures, Philips Brilliance CT's Comprehensive Cardiac Analysis (CCA) package uses a 3D CT segmentation of the coronary tree to select and visualize the best 2D C-arm projections for use in planning for percutaneous coronary interventional (PCI) procedures.

October 15, 2008 - Philips is showing for the first time at TCT, the CX50 CompactXtreme ultrasound system, which brings premium technologies from the Philips iE33 system to a compact form.

October 14, 2008 - CoreValve said the expanded clinical evaluation of its ReValving System for percutaneous aortic valve replacement (PAVR) in high-risk patients with aortic stenosis continues to enroll patients at an accelerating pace.

More than 1,800 patients have now been treated worldwide at nearly 100 centers in 20 countries.

October 13, 2008 — Data from an independent meta-analysis of Abbott Vascular’s SPIRIT II and SPIRIT III randomized clinical trials demonstrated that the XIENCE V Everolimus Eluting Coronary Stent System continues to deliver clinically significant benefits for patients compared to the TAXUS paclitaxeleluting coronary stent system out to two years, said Abbott.

October 14, 2008 - Edwards Lifesciences Corp. released new data from two studies of the Edwards SAPIEN transcatheter aortic heart valve with the RetroFlex transfemoral delivery system at TCT 2008.

October 14, 2008 – Medtronic released, at TCT 2008, new data from the ENDEAVOR clinical program that reinforces the consistently strong performance of the company’s Endeavor drug-eluting stent (DES) across diverse patient populations affected by coronary artery disease.

One-year results from the ENDEAVOR-Five registry – including those for subsets of diabetics and patients with acute myocardial infarction (AMI) – demonstrate that the Endeavor DES performs comparably in a real-world population of patients with complex disease and in specific patient subsets.

The Philips cath lab experience provides interaction between image acquisition and visualization technologies, hemodynamic monitoring and charting, cath lab and statistical reporting and multimodality image access, viewing and storage.

CT Comprehensive Cardiac Analysis (CCA) with 3D-QCA from Philips is used to perform detailed evaluation of the coronary arteries and advanced ventricular functional analysis.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now